Renaissance Technologies LLC Sells 23,026 Shares of MediWound Ltd. (NASDAQ:MDWD)

Renaissance Technologies LLC lowered its stake in shares of MediWound Ltd. (NASDAQ:MDWD - Free Report) by 66.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,418 shares of the biopharmaceutical company's stock after selling 23,026 shares during the quarter. Renaissance Technologies LLC owned about 0.11% of MediWound worth $203,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in MDWD. Russell Investments Group Ltd. boosted its position in shares of MediWound by 154.1% during the 4th quarter. Russell Investments Group Ltd. now owns 1,916 shares of the biopharmaceutical company's stock worth $34,000 after acquiring an additional 1,162 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of MediWound by 3.6% during the fourth quarter. Geode Capital Management LLC now owns 98,710 shares of the biopharmaceutical company's stock worth $1,757,000 after buying an additional 3,408 shares in the last quarter. Essex Investment Management Co. LLC boosted its holdings in shares of MediWound by 30.7% during the 4th quarter. Essex Investment Management Co. LLC now owns 148,949 shares of the biopharmaceutical company's stock valued at $2,651,000 after acquiring an additional 35,012 shares in the last quarter. Yelin Lapidot Holdings Management Ltd. boosted its stake in shares of MediWound by 13.4% during the fourth quarter. Yelin Lapidot Holdings Management Ltd. now owns 851,361 shares of the biopharmaceutical company's stock valued at $15,154,000 after purchasing an additional 100,618 shares in the last quarter. Finally, Rhumbline Advisers raised its holdings in MediWound by 7.3% in the 4th quarter. Rhumbline Advisers now owns 10,835 shares of the biopharmaceutical company's stock valued at $193,000 after buying an additional 739 shares during the last quarter. Institutional investors own 46.83% of the company's stock.

MediWound Price Performance

Shares of MDWD stock traded up $0.06 on Friday, hitting $17.52. The stock had a trading volume of 28,295 shares, compared to its average volume of 88,204. The business has a 50 day moving average of $16.96 and a 200 day moving average of $17.46. MediWound Ltd. has a 12-month low of $12.78 and a 12-month high of $24.00. The stock has a market cap of $189.36 million, a price-to-earnings ratio of -6.04 and a beta of 0.30.

MediWound (NASDAQ:MDWD - Get Free Report) last issued its quarterly earnings results on Wednesday, March 19th. The biopharmaceutical company reported ($0.36) EPS for the quarter, beating analysts' consensus estimates of ($0.59) by $0.23. The company had revenue of $5.84 million during the quarter, compared to the consensus estimate of $5.79 million. MediWound had a negative return on equity of 82.17% and a negative net margin of 142.29%. During the same period last year, the business posted ($0.19) earnings per share. As a group, research analysts expect that MediWound Ltd. will post -2.66 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently issued reports on MDWD shares. StockNews.com raised MediWound to a "sell" rating in a research report on Friday, March 21st. Craig Hallum assumed coverage on shares of MediWound in a research note on Friday, February 28th. They issued a "buy" rating and a $39.00 price objective for the company. HC Wainwright reiterated a "buy" rating and set a $25.00 price objective on shares of MediWound in a report on Thursday, March 20th. Finally, Alliance Global Partners initiated coverage on MediWound in a report on Friday, May 2nd. They issued a "buy" rating and a $25.00 price target on the stock. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. According to MarketBeat, MediWound presently has a consensus rating of "Moderate Buy" and an average target price of $29.75.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.